Kineta (KA) Delisting to OTC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq futures surge 2% as chip outlook calms AI jitters; inflation data awaited
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Kineta, Inc Transitioning from Nasdaq to OTC Markets
September 19, 2024 6:23 PM EDTKineta will be trading under the symbol KANT on OTC Pink
Kineta will continue to pursue strategic alternatives as previously announced
TuHURA Biosciences has an exclusivity right and a right of first offer for Kinetas KVA12123 program
The ongoing KVA12123 Phase 1 study is open for new patient enrollment and following those patients previously enrolled.
SEATTLE, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer... More
